NASDAQ:TBPH Theravance Biopharma (TBPH) Stock Price, News & Analysis $8.10 0.00 (0.00%) (As of 10/4/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Theravance Biopharma Stock (NASDAQ:TBPH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Theravance Biopharma alerts:Sign Up Key Stats Today's Range$8.07▼$8.2150-Day Range$7.66▼$10.1152-Week Range$7.44▼$11.71Volume239,152 shsAverage Volume211,988 shsMarket Capitalization$393.93 millionP/E RatioN/ADividend YieldN/APrice Target$13.75Consensus RatingHold Company OverviewTheravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.Read More… Elon Musk’s chilling warning for humanity (Ad)The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern border is a travesty, but the 'invasion' I've found will have 10 times greater effects on our economy, and ultimately our way of life.Go here to see why. Theravance Biopharma Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks42nd Percentile Overall ScoreTBPH MarketRank™: Theravance Biopharma scored higher than 42% of companies evaluated by MarketBeat, and ranked 698th out of 994 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingTheravance Biopharma has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageTheravance Biopharma has only been the subject of 4 research reports in the past 90 days.Read more about Theravance Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Theravance Biopharma are expected to grow in the coming year, from ($1.04) to $0.19 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Theravance Biopharma is -9.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Theravance Biopharma is -9.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTheravance Biopharma has a P/B Ratio of 1.89. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Theravance Biopharma's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.90% of the float of Theravance Biopharma has been sold short.Short Interest Ratio / Days to CoverTheravance Biopharma has a short interest ratio ("days to cover") of 13.7, which indicates bearish sentiment.Change versus previous monthShort interest in Theravance Biopharma has recently decreased by 1.29%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTheravance Biopharma does not currently pay a dividend.Dividend GrowthTheravance Biopharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted11.90% of the float of Theravance Biopharma has been sold short.Short Interest Ratio / Days to CoverTheravance Biopharma has a short interest ratio ("days to cover") of 13.7, which indicates bearish sentiment.Change versus previous monthShort interest in Theravance Biopharma has recently decreased by 1.29%, indicating that investor sentiment is improving. News and Social Media1.3 / 5News Sentiment0.31 News SentimentTheravance Biopharma has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Theravance Biopharma this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for TBPH on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Theravance Biopharma insiders have bought 21,562.33% more of their company's stock than they have sold. Specifically, they have bought $7,798,440.00 in company stock and sold $36,000.00 in company stock.Percentage Held by InsidersOnly 6.90% of the stock of Theravance Biopharma is held by insiders.Percentage Held by Institutions99.10% of the stock of Theravance Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Theravance Biopharma's insider trading history. Receive TBPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Theravance Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address TBPH Stock News HeadlinesInvest Alongside Wall Street Legend Seth Klarman: 2 New Stocks He Bought and 1 He DumpedSeptember 29, 2024 | 247wallst.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Receives $13.75 Average Target Price from AnalystsSeptember 28, 2024 | americanbankingnews.comRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT make you rich. However, there is one stock that stands head and shoulders above everything else. It's currently trading for only $15...October 6, 2024 | Behind the Markets (Ad)Buy Rating Affirmed for Theravance Biopharma on Yupelri Growth and Ampreloxetine Pipeline ProgressSeptember 16, 2024 | markets.businessinsider.comSeth Klarman's Complete Exit from Theravance Biopharma IncSeptember 11, 2024 | finance.yahoo.comHere's Why We're Not At All Concerned With Theravance Biopharma's (NASDAQ:TBPH) Cash Burn SituationSeptember 6, 2024 | finance.yahoo.comTheravance Biopharma to Participate in an Upcoming Investor ConferenceAugust 27, 2024 | prnewswire.comSeth Klarman's Strategic Reduction in Theravance Biopharma IncAugust 15, 2024 | finance.yahoo.comSee More Headlines TBPH Stock Analysis - Frequently Asked Questions How have TBPH shares performed this year? Theravance Biopharma's stock was trading at $11.24 at the beginning of 2024. Since then, TBPH shares have decreased by 27.9% and is now trading at $8.10. View the best growth stocks for 2024 here. How were Theravance Biopharma's earnings last quarter? Theravance Biopharma, Inc. (NASDAQ:TBPH) announced its quarterly earnings results on Monday, August, 5th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by $0.25. The biopharmaceutical company earned $14.26 million during the quarter, compared to analyst estimates of $15.81 million. Theravance Biopharma had a negative net margin of 73.61% and a negative trailing twelve-month return on equity of 21.29%. Who are Theravance Biopharma's major shareholders? Top institutional shareholders of Theravance Biopharma include SG Americas Securities LLC (0.03%). Insiders that own company stock include Richard A Graham and Rhonda Farnum. View institutional ownership trends. How do I buy shares of Theravance Biopharma? Shares of TBPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Theravance Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Theravance Biopharma investors own include Gilead Sciences (GILD), Bausch Health Companies (BHC), Exelixis (EXEL), SCYNEXIS (SCYX), Teva Pharmaceutical Industries (TEVA), Johnson & Johnson (JNJ) and Merck & Co., Inc. (MRK). Company Calendar Last Earnings8/05/2024Today10/06/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TBPH Previous SymbolNASDAQ:TBPHV CUSIPN/A CIK1583107 Webwww.theravance.com Phone(650) 808-6000FaxN/AEmployees359Year FoundedN/APrice Target and Rating Average Stock Price Target$13.75 High Stock Price Target$21.00 Low Stock Price Target$9.00 Potential Upside/Downside+69.8%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-55,190,000.00 Net Margins-73.61% Pretax Margin-61.63% Return on Equity-21.29% Return on Assets-11.94% Debt Debt-to-Equity RatioN/A Current Ratio5.20 Quick Ratio5.20 Sales & Book Value Annual Sales$62.02 million Price / Sales6.35 Cash FlowN/A Price / Cash FlowN/A Book Value$4.28 per share Price / Book1.89Miscellaneous Outstanding Shares48,633,000Free Float45,277,000Market Cap$393.93 million OptionableOptionable Beta0.25 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report This page (NASDAQ:TBPH) was last updated on 10/6/2024 by MarketBeat.com Staff From Our PartnersElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored"Doomsday indicator” flashing for the first time since the Great Depression...It's been a bloodbath in the markets. The seven most valuable US tech companies lost a combined $1 trillion...Behind the Markets | SponsoredWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAI Expert Reveals New PickEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theravance Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theravance Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.